Do Vaccines Cause Autism? What the Vaccine Injury Court Actually Found in the Autism Test Cases
The Vaccine Injury Court examined hundreds of studies on vaccines and autism. Learn what the Omnibus Autism Proceeding actually decided—and why encephalitis cases may still be compensable.
For more than twenty years, courts and scientists have examined one of the most controversial questions in modern medicine: can vaccines cause autism? The issue reached its legal and scientific peak during the Omnibus Autism Proceeding (OAP) in the Vaccine Injury Compensation Program, where the Court reviewed hundreds of medical studies and expert opinions in test cases such as Cedillo, Hazlehurst, Snyder, King, Dwyer, and Mead. The court ultimately concluded that the medical literature does not show that vaccines themselves cause autism. But that ruling is frequently misunderstood. The Vaccine Court did not hold that developmental disorders can never follow a vaccine injury. In fact, certain neurological injuries—such as autoimmune encephalitis—can produce developmental regression and autism-like symptoms and may be compensable under the Vaccine Injury Compensation Program.
Medical Literature Review
To fully understand the scientific and legal issues surrounding vaccines, autism, and neurological injuries, readers should review research and policy statements from leading public health and medical institutions. The Omnibus Autism Proceeding relied heavily on peer-reviewed literature and expert testimony drawn from many of these same sources.
Centers for Disease Control and Prevention (CDC)
The Centers for Disease Control and Prevention (CDC) has conducted and reviewed numerous epidemiological studies evaluating whether vaccines are associated with autism. These studies examine large populations of children and track vaccination history and developmental outcomes.
Examples include CDC-supported research analyzing hundreds of thousands of children across multiple countries. These studies consistently found no epidemiological association between the MMR vaccine and autism and no evidence linking thimerosal exposure to autism rates.
The CDC continues to monitor vaccine safety through surveillance systems such as:
Vaccine Safety Datalink (VSD)
Vaccine Adverse Event Reporting System (VAERS)
Clinical Immunization Safety Assessment (CISA) Project
These programs collect and analyze data to detect potential vaccine-related adverse events and guide future research.
National Institutes of Health (NIH)
The National Institutes of Health (NIH) supports extensive research into the causes of autism spectrum disorder and neurological development.
NIH-funded studies have identified several potential contributors to autism, including:
genetic susceptibility
prenatal developmental factors
environmental influences
immune system dysfunction
early neurological injury
The NIH has also funded research into autoimmune encephalitis and neuroinflammatory conditions, which can produce developmental regression and autism-like symptoms in children. This body of research highlights how immune-mediated brain inflammation may disrupt neural development.
National Academy of Medicine (Formerly Institute of Medicine)
The National Academy of Medicine (NAM)—formerly the Institute of Medicine—conducted some of the most comprehensive reviews of vaccine safety.
Two landmark reports evaluated the relationship between vaccines and autism:
Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism (2001)
Immunization Safety Review: Vaccines and Autism (2004)
These reports reviewed epidemiological studies, clinical data, and biological research. Both reports concluded that the evidence favors rejection of a causal relationship between vaccines and autism.
These findings played an important role in shaping the scientific framework discussed in the Vaccine Court’s autism test cases.
Peer-Reviewed Medical Journals
Much of the scientific evidence examined in the Omnibus Autism Proceeding came from peer-reviewed journals such as:
The Lancet
New England Journal of Medicine
Pediatrics
Journal of Autism and Developmental Disorders
BMJ
Journal of Child Psychology and Psychiatry
These journals publish rigorous scientific studies that undergo expert review before publication.
The Vaccine Court evaluated dozens of studies from these journals, including large epidemiological analyses involving hundreds of thousands of children, molecular virology research examining measles virus persistence, and toxicology studies examining mercury metabolism.
The Importance of Ongoing Scientific Research
The Omnibus Autism Proceeding reflected the best available scientific evidence at the time those cases were litigated. However, science continues to evolve as new data and research methods become available.
Continued research is essential to understanding rare neurological conditions that may follow vaccination, including:
autoimmune encephalitis
immune-mediated encephalopathy
neuroinflammatory disorders
developmental regression following neurological injury
Encouraging rigorous scientific research—while ensuring that individuals who suffer genuine vaccine-related neurological injuries receive fair compensation—is consistent with the goals of the Vaccine Injury Compensation Program.
Scientific inquiry, not speculation, remains the most reliable path toward understanding the complex causes of autism and other neurological conditions.
Autism Litigation Science Explained
The Omnibus Autism Proceeding involved one of the most extensive reviews of scientific literature ever conducted in vaccine litigation. The record contained hundreds of scientific articles addressing epidemiology, virology, toxicology, neurology, and immunology. The following section summarizes the principal medical literature discussed in the opinions, including the content of each article, the scientific positions advanced by the authors, and how the court ultimately treated each article in evaluating the competing causation theories.
Andrew Wakefield et al.
“Ileal-Lymphoid-Nodular Hyperplasia, Non-Specific Colitis, and Pervasive Developmental Disorder in Children” (Lancet, 1998)
Premise
This paper examined twelve children who presented with gastrointestinal symptoms and developmental disorders, including autism. The authors explored whether a relationship might exist between intestinal inflammation and developmental regression. Several parents reported that behavioral symptoms appeared after MMR vaccination.
Results
The researchers observed ileal lymphoid nodular hyperplasia and colitis in the children’s intestinal biopsies. The study documented gastrointestinal abnormalities but did not include a control group, statistical analysis, or epidemiological comparison.
Conclusions of the Authors
The authors suggested that a possible association between MMR vaccination, intestinal inflammation, and developmental regression warranted further investigation. They did not claim to prove causation.
Court’s Evaluation
The OAP decisions considered the article historically important but scientifically weak because it was a small uncontrolled case series incapable of establishing causation.
V. Uhlmann et al.
“Potential Viral Pathogenic Mechanism for New Variant Inflammatory Bowel Disease” (2002)
Premise
This molecular biology study attempted to determine whether measles virus RNA could be detected in intestinal tissue from children with developmental disorders and gastrointestinal disease.
Results
Using PCR testing, the researchers reported finding measles virus RNA in a high proportion of intestinal biopsy samples from affected children and in relatively few controls.
Conclusions of the Authors
The authors concluded that the results supported the possibility of a persistent measles infection contributing to inflammatory bowel disease in children with developmental disorders.
Court’s Evaluation
The OAP decisions treated this article as the central scientific support for the measles-persistence theory but ultimately rejected it due to methodological problems, lack of sequencing confirmation, and inability to replicate the findings.
Yasmin D’Souza, Eric Fombonne & Brian Ward
“No Evidence of Persisting Measles Virus in Peripheral Blood Mononuclear Cells From Children With Autism Spectrum Disorder” (2006)
Premise
This study tested whether measles virus RNA could be detected in blood cells of children with autism using PCR techniques.
Results
Researchers found no evidence of measles virus persistence in the blood samples of autistic children. The study also demonstrated that earlier PCR primers used in other studies could generate false positive signals.
Conclusions of the Authors
The authors concluded that their results did not support the hypothesis that persistent measles virus infection contributes to autism.
Court’s Evaluation
The OAP decisions treated this article as strong contrary evidence and as a methodological explanation for why earlier measles-detection studies may have produced false positives.
Y. D’Souza et al.
“No Evidence of Persisting Measles Virus in the Intestinal Tissues of Patients with Inflammatory Bowel Disease” (2007)
Premise
This follow-up study examined intestinal biopsy samples to determine whether measles virus RNA could be detected in bowel tissue.
Results
Using improved PCR techniques and sequencing confirmation, researchers found no evidence of persistent measles virus in intestinal tissues.
Conclusions of the Authors
The authors concluded that there was no molecular evidence supporting persistent measles virus infection in intestinal tissue.
Court’s Evaluation
Because the study examined the same tissue type used in earlier positive reports, the court considered it strong evidence undermining the measles persistence hypothesis.
Brent Taylor et al.
“Autism and Measles, Mumps, and Rubella Vaccine: No Epidemiological Evidence for a Causal Association” (1999)
Premise
This epidemiological study examined whether autism diagnoses increased after the introduction of the MMR vaccine in the United Kingdom.
Results
Researchers analyzed autism diagnoses and vaccination histories and found no temporal association between MMR vaccination and autism onset.
Conclusions of the Authors
The study concluded that epidemiological data did not support a causal relationship between the MMR vaccine and autism.
Court’s Evaluation
The court relied heavily on this study as early epidemiological evidence refuting the MMR-autism hypothesis.
Kreesten Madsen et al.
“A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism” (New England Journal of Medicine, 2002)
Premise
This large Danish cohort study examined whether children who received MMR vaccination had a higher incidence of autism than unvaccinated children.
Results
The study followed more than 500,000 children and found no increased risk of autism among vaccinated children.
Conclusions of the Authors
The researchers concluded that MMR vaccination does not increase the risk of autism.
Court’s Evaluation
The OAP decisions treated this study as highly persuasive epidemiological evidence because of its large population size and rigorous methodology.
Liam Smeeth et al.
“MMR Vaccination and Pervasive Developmental Disorders: A Case-Control Study” (2004)
Premise
This case-control study compared vaccination histories of children with autism spectrum disorders and children without autism.
Results
The study found no increased odds of autism among children who had received the MMR vaccine.
Conclusions of the Authors
The authors concluded that MMR vaccination was not associated with pervasive developmental disorders.
Court’s Evaluation
The court treated this study as further epidemiological confirmation that MMR vaccination does not cause autism.
H. Honda et al.
“No Effect of MMR Withdrawal on the Incidence of Autism: A Total Population Study” (2005)
Premise
This ecological study examined autism incidence in Japan after the country discontinued use of the MMR vaccine.
Results
Autism diagnoses continued to increase even after MMR vaccination was discontinued.
Conclusions of the Authors
The authors concluded that withdrawal of MMR had no effect on autism rates.
Court’s Evaluation
The court considered this study powerful “natural experiment” evidence contradicting the claim that MMR causes autism.
Samuel Goth et al.
“Uncoupling of ATP-Mediated Calcium Signaling and Dysregulated Interleukin-6 Secretion in Dendritic Cells by Nanomolar Thimerosal”
Premise
This laboratory study examined how thimerosal exposure affects immune signaling in dendritic cells.
Results
The researchers observed changes in calcium signaling and cytokine secretion in cultured cells exposed to thimerosal.
Conclusions of the Authors
The study suggested that thimerosal could influence immune signaling pathways.
Court’s Evaluation
The court found the article limited because it involved in vitro cell experiments and did not demonstrate real-world neurological injury in humans.
Anshu Agrawal et al.
“Thimerosal Induces TH2 Responses via Influencing Cytokine Secretion by Human Dendritic Cells”
Premise
This study investigated whether thimerosal exposure alters immune system signaling in human dendritic cells.
Results
Researchers observed cytokine changes indicating a TH2-type immune response when cells were exposed to thimerosal.
Conclusions of the Authors
The authors concluded that thimerosal could influence cytokine signaling in immune cells.
Court’s Evaluation
The OAP decisions treated the study as insufficient to demonstrate vaccine-related immune injury because it involved laboratory conditions rather than real-world exposures.
A.S. Holmes et al.
“Reduced Levels of Mercury in First Baby Haircuts of Autistic Children”
Premise
This observational study tested whether mercury levels in hair samples differed between autistic children and controls.
Results
The authors reported lower mercury levels in hair samples from autistic children.
Conclusions of the Authors
They hypothesized that autistic children might have impaired mercury excretion.
Court’s Evaluation
The court found the study unreliable due to methodological flaws and questionable control data.
J.J. Bradstreet et al.
“A Case-Control Study of Mercury Burden in Children with Autistic Spectrum Disorders”
Premise
This study attempted to measure mercury burden in autistic children through chelation-challenge urine testing.
Results
Autistic children were reported to excrete higher levels of mercury following chelation therapy.
Conclusions of the Authors
The authors suggested the findings supported increased mercury burden in autism.
Court’s Evaluation
The court rejected the study due to flawed methodology, unreliable testing protocols, and weak statistical analysis.
Sarah Soden et al.
“24-Hour Provoked Urine Excretion Test for Heavy Metals in Children with Autism and Typically Developing Controls”
Premise
This pilot study examined whether autistic children retained higher levels of mercury using chelation-challenge testing.
Results
The study found no meaningful difference in mercury excretion between autistic children and controls.
Conclusions of the Authors
The authors concluded that the findings did not support mercury retention in autism.
Court’s Evaluation
The court treated the study as credible evidence contradicting the mercury-retention hypothesis.
E. Fombonne & S. Chakrabarti
“No Evidence for a New Variant of Measles-Mumps-Rubella-Induced Autism” (Pediatrics, 2001)
Premise
This article addressed a central claim that emerged after Wakefield’s work: that even if MMR did not cause autism generally, it might cause a “new variant” marked by regression and gastrointestinal symptoms. The study was an epidemiologic/phenotype analysis of autistic children in the United Kingdom designed to determine whether the introduction of MMR was associated with a change in the frequency or pattern of regressive autism.
Results
The authors found no increase in the proportion of regressive autism after the introduction of MMR. The rate of regression remained stable over time. The article therefore did not support the claim that MMR created a new subtype of autism.
Conclusions of the Authors
The authors concluded that there was no evidence for a new variant of autism induced by MMR vaccination.
Court’s Evaluation
The OAP decisions treated this study as especially important because it directly tested the “new variant” theory rather than autism generally. The courts relied on it as affirmative evidence that regressive autism was not meaningfully altered by the advent of MMR.
Brent Taylor et al.
“Measles, Mumps, and Rubella Vaccination and Bowel Problems or Developmental Regression in Children with Autism: Population Study” (BMJ, 2002)
Premise
This epidemiological study tested the refined Wakefield theory that MMR might be associated specifically with bowel problems or developmental regression within autism, rather than with autism as a whole. The study looked at autistic children and examined whether bowel symptoms or regression correlated with MMR exposure or timing.
Results
The study found no association between MMR vaccination and bowel problems, and no association between MMR vaccination and developmental regression. It also found that the proportion of regressive autism within autism cases did not rise after the introduction of MMR.
Conclusions of the Authors
The authors concluded that the data did not support a causal association between MMR and either bowel problems or developmental regression in children with autism.
Court’s Evaluation
The special masters treated Taylor 2002 as one of the strongest studies against petitioners’ narrower theory. It was particularly valuable because it directly addressed the regression/GI hypothesis rather than only autism in the aggregate.
J. Richler et al.
“Is There a ‘Regressive Phenotype’ of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine? A CPEA Study” (Journal of Autism and Developmental Disorders, 2006)
Premise
This study was designed specifically to determine whether regressive autism is a distinct phenotype and, if so, whether it is associated with the timing of MMR vaccination. The study compared autistic children with regression to autistic children without regression and evaluated developmental patterns and vaccine timing.
Results
The researchers found some group differences between children with and without regression, but no evidence that those differences were associated with MMR timing. The data did not show that regression clustered around MMR exposure.
Conclusions of the Authors
The authors concluded that the evidence did not support a regressive phenotype associated with MMR vaccination.
Court’s Evaluation
The OAP courts considered Richler one of the most important studies on regression because it asked the exact question petitioners were pressing. The courts relied on it heavily in rejecting the argument that MMR could still cause a narrow subgroup of “regressive” autism even if it did not cause autism generally.
T. Uchiyama et al.
“MMR-Vaccine and Regression in Autism Spectrum Disorders: Negative Results Presented from Japan” (Journal of Autism and Developmental Disorders, 2007)
Premise
This Japanese study tested whether children with autism who received MMR had a higher rate of regression than children with autism who did not receive MMR. It was aimed directly at the claim that MMR causes regressive autism.
Results
The study found no increased regression rate among Japanese autistic children who had received MMR compared with those who had not. The regression rates were not higher in the exposed group.
Conclusions of the Authors
The authors concluded that their findings disconfirmed the hypothesis that MMR vaccination causes regression in autism spectrum disorders.
Court’s Evaluation
The OAP opinions repeatedly cited Uchiyama as direct evidence against the regression theory. The special masters treated it as especially probative because it specifically addressed the very subgroup petitioners insisted had been missed in broader epidemiologic studies.
Liam Smeeth et al.
“MMR Vaccination and Pervasive Developmental Disorders: A Case-Control Study” (Lancet, 2004)
Premise
This case-control epidemiology study examined whether children with pervasive developmental disorders differed from controls in their rates or timing of MMR vaccination.
Results
The study found no increased odds of pervasive developmental disorders among children who received MMR. The vaccination histories of the autism cases and controls did not support a causal link.
Conclusions of the Authors
The authors concluded that MMR vaccination was not associated with pervasive developmental disorders.
Court’s Evaluation
The special masters treated this as another competent epidemiologic study that failed to show an association. It strengthened the courts’ view that negative results were appearing across different study designs, not only in cohort analyses.
S. DeWilde et al.
“Do Children Who Become Autistic Consult More Often After MMR Vaccination?” (British Journal of General Practice, 2001)
Premise
This study asked whether children later diagnosed with autism had an increase in doctor consultations shortly after MMR vaccination, which might be expected if the vaccine precipitated noticeable behavioral or medical decline.
Results
The researchers found no increased consultation rate in the autism group compared with controls during the six months following MMR vaccination.
Conclusions of the Authors
The authors concluded that the data did not support the idea of a post-MMR behavioral decline detectable in routine medical consultations.
Court’s Evaluation
The courts treated this as one more epidemiologic study cutting against the MMR theory. Although not as central as Taylor or Madsen, it helped show the absence of any medical-utilization signal after vaccination.
Larry Dales et al.
“Time Trends in Autism and in MMR Immunization Coverage in California” (JAMA, 2001)
Premise
This ecological study examined whether autism rates in California moved in a way that corresponded to changes in MMR immunization coverage.
Results
The authors found no correlation between increasing autism diagnoses and shifts in the age or coverage of MMR vaccination. The epidemiologic trends did not track one another in a way consistent with causation.
Conclusions of the Authors
The authors concluded that the time trends did not support a causal relationship between MMR coverage and autism rates.
Court’s Evaluation
The OAP decisions cited this article as part of the larger body of ecological evidence showing that autism trends did not align with MMR policy or uptake in the way petitioners’ theory would predict.
Eric Fombonne
“Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links with Immunizations” (Pediatrics, 2006)
Premise
This Canadian epidemiology study examined autism prevalence and potential links with immunizations, including whether rates differed after first and second MMR doses.
Results
The study found no increased autism risk after the second MMR dose and no epidemiologic pattern supporting a vaccine-autism relationship.
Conclusions of the Authors
The authors concluded that the data did not support a causal link between immunization and pervasive developmental disorders.
Court’s Evaluation
The special masters treated this article as another competent study from a different setting showing the same negative pattern. It reinforced the point that the negative epidemiology was international and consistent.
H. Honda et al.
“No Effect of MMR Withdrawal on the Incidence of Autism: A Total Population Study” (Journal of Child Psychology and Psychiatry, 2005)
Premise
This ecological Japanese study asked what happened to autism incidence after MMR was withdrawn. It functioned as a natural experiment: if MMR caused autism, autism incidence should have declined after the vaccine’s removal.
Results
Autism rates continued to rise in birth cohorts after MMR was no longer administered. There was no drop in incidence during the period of non-use.
Conclusions of the Authors
The authors concluded that MMR was unlikely to cause a substantial proportion of autism cases.
Court’s Evaluation
The OAP courts gave Honda substantial weight. They repeatedly pointed to it as easy-to-understand evidence that autism trends did not respond to MMR withdrawal in the way a causal theory would predict.
Hviid et al.
“Association Between Thimerosal-Containing Vaccines and Autism” (JAMA, 2003)
Premise
This Danish cohort study evaluated whether children exposed to thimerosal-containing vaccines had a higher incidence of autism than children who were not exposed.
Results
The study found no increased risk of autism associated with thimerosal exposure. The comparison between exposed and unexposed groups did not reveal a meaningful association.
Conclusions of the Authors
The authors concluded that their results did not support a relationship between thimerosal-containing vaccines and autism.
Court’s Evaluation
The thimerosal test-case opinions treated Hviid as one of the principal epidemiologic studies against petitioners’ theory. Petitioners’ expert Dr. Greenland argued that the confidence intervals did not rule out a tiny risk in a subgroup, but the courts still regarded Hviid as strong evidence against a general association.
K.M. Madsen et al.
“Thimerosal and the Occurrence of Autism: Negative Ecological Evidence From Danish Population-Based Data” (Pediatrics, 2003)
Premise
This ecological study examined what happened to autism rates in Denmark after thimerosal was removed from vaccines.
Results
Autism rates continued to increase even after thimerosal was discontinued. The expected decline did not occur.
Conclusions of the Authors
The authors concluded that the data did not support a causal correlation between thimerosal in vaccines and autism incidence.
Court’s Evaluation
The courts treated Madsen as one of the key ecological studies undermining the thimerosal hypothesis. Petitioners argued that ecological studies could miss a very small subgroup effect, but the special masters found the continued increase after thimerosal removal to be inconsistent with petitioners’ broader claim.
T. Verstraeten et al.
“Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases” (Pediatrics, 2003)
Premise
This study examined large HMO databases in the United States to determine whether different levels of thimerosal exposure were associated with neurodevelopmental outcomes, including autism.
Results
The study found no clear association between thimerosal exposure and autism. Petitioners pointed to language in the article suggesting that some questions remained unresolved, but the overall results did not show a persuasive autism signal.
Conclusions of the Authors
The authors did not conclude that thimerosal caused autism; rather, the study did not confirm a causal association and was part of the broader body of literature finding no clear link.
Court’s Evaluation
The thimerosal decisions treated Verstraeten as part of the consistent negative epidemiology. Petitioners’ expert emphasized its cautionary wording, but the courts viewed the article in the context of the larger literature, which overwhelmingly pointed the same way.
P. Stehr-Green et al.
“Autism and Thimerosal-Containing Vaccines: Lack of Consistent Evidence for an Association” (American Journal of Preventive Medicine, 2003)
Premise
This ecological study compared autism trends in California, Denmark, and Sweden, including settings where thimerosal had been discontinued.
Results
The study found increasing autism rates despite differences in thimerosal exposure and despite thimerosal removal in Denmark and Sweden.
Conclusions of the Authors
The authors concluded that there was no consistent evidence for an association between thimerosal-containing vaccines and autism.
Court’s Evaluation
The OAP special masters treated this article as another important ecological study showing that autism trends did not follow thimerosal exposure patterns. It reinforced the broader point that the epidemiology was remarkably consistent.
N. Andrews et al.
“Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association” (Pediatrics, 2004)
Premise
This retrospective U.K. cohort study examined infant thimerosal exposure and later developmental disorders, including autism-related outcomes.
Results
The study found no relationship between thimerosal dose and autism. It also looked at a large population that included low-birth-weight infants.
Conclusions of the Authors
The authors concluded that the data did not support a causal association between thimerosal exposure and developmental disorders.
Court’s Evaluation
The courts treated Andrews as a substantial cohort study that directly contradicted petitioners’ theory. Petitioners argued subgroup effects could still be missed, but the special masters regarded the article as strong contrary evidence.
Jon Heron et al.
“Thimerosal Exposure in Infants and Developmental Disorders: A Prospective Cohort Study in the United Kingdom Does Not Support a Causal Association” (Pediatrics, 2004)
Premise
This prospective cohort study followed approximately 13,000 British children from birth to school age and assessed whether early thimerosal exposure was associated with developmental problems.
Results
The study did not use autism as a formal endpoint, but it did evaluate special educational needs and found no association between thimerosal exposure and those outcomes.
Conclusions of the Authors
The authors concluded that the study did not support a causal relationship between thimerosal exposure and developmental disorders.
Court’s Evaluation
The special masters acknowledged that Heron did not specifically use autism as an endpoint, but they still regarded it as relevant because autistic children often require special educational services. It was treated as additional evidence against a thimerosal-developmental injury theory.
Eric Fombonne et al.
“Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links with Immunizations” (Pediatrics, 2006)
Premise
This study examined autism prevalence in Montreal and changes in immunization practices, including changes involving thimerosal and MMR scheduling.
Results
The researchers found no correlation between autism prevalence and changes in immunization exposures.
Conclusions of the Authors
The authors concluded that the data did not support a link between immunizations and pervasive developmental disorders.
Court’s Evaluation
The OAP thimerosal cases treated this as one of the important international epidemiologic studies showing no relationship between changing vaccine exposures and autism prevalence.
Robert Schechter & Judith Grether
“Continuing Increases in Autism Reported to California’s Developmental Services System: Mercury in Retrograde” (Archives of General Psychiatry, 2008)
Premise
This ecological study examined California autism-service data after the phase-out of thimerosal from childhood vaccines. The theory tested was simple: if thimerosal were a major cause of autism, cases should fall after its removal.
Results
The number of autistic children reported to the California developmental services system continued to climb during the years when a decline would have been expected if thimerosal were causal.
Conclusions of the Authors
The authors concluded that the results were inconsistent with the hypothesis that thimerosal had been a primary cause of autism in California.
Court’s Evaluation
The thimerosal special masters cited Schechter and Grether as one of the clearest ecological refutations of petitioners’ overall theory. The study was treated as strong evidence that autism trends did not respond to thimerosal removal.
Hershel Jick & James A. Kaye
“Autism and DPT Vaccination in the United Kingdom” (New England Journal of Medicine letter, 2004)
Premise
This was a short report, published as a letter, comparing autistic children and controls in the United Kingdom to see whether there was any difference in exposure to thimerosal-containing DPT vaccination.
Results
The study found no significant difference between autistic children and controls with respect to thimerosal exposure.
Conclusions of the Authors
The authors commented that the findings provided further support for the view that exposure to mercury in vaccines was not the cause of the rising incidence of autism.
Court’s Evaluation
The special masters treated the results as generally consistent with the other negative studies, but they gave the article diminished weight because it was published only as a short letter rather than a full article and because the published note disclosed consultancy work for a vaccine manufacturer’s counsel. Thus, the study was not rejected on its face, but was considered less weighty than the other epidemiologic articles.
William W. Thompson et al.
“Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years” (New England Journal of Medicine, 2007)
Premise
This U.S. study examined whether early thimerosal exposure was associated with later neuropsychological deficits in children aged seven to ten years. It did not use autism as a formal endpoint, but it included speech, language, and intellectual-function measures relevant to autism-like concerns.
Results
The study generally found no association between early thimerosal exposure and adverse neuropsychological outcomes.
Conclusions of the Authors
The authors concluded that the results did not support an association between thimerosal exposure and deficits in neuropsychological functioning.
Court’s Evaluation
The OAP thimerosal decisions treated Thompson as relevant supportive evidence against petitioners’ theory, even though autism itself was not a formal endpoint. The courts viewed it as another indication that thimerosal exposure was not producing the kind of neurological deficits petitioners posited.
A. Hviid, K.M. Madsen, Stehr-Green, Andrews, Verstraeten, Heron, Fombonne, Schechter, Jick, and Thompson — Collective Court Treatment
Across the thimerosal test cases, the courts repeatedly emphasized not merely that one or two studies were negative, but that numerous research groups in several countries, using several different study designs, all failed to find evidence that thimerosal-containing vaccines are associated with autism. The courts specifically summarized these studies as part of a unified epidemiologic record pointing in the same direction. Petitioners’ expert Dr. Greenland argued that the studies could not exclude a tiny, rare subgroup of “clearly regressive autism,” but he also conceded that the studies had not proved petitioners’ theory and that he had no autism expertise of his own. The special masters accepted that epidemiology can never rule out every hypothetical sliver of possibility, but concluded that the actual evidence overwhelmingly weighed against petitioners’ claims.
Geier & Geier
“A Comparative Evaluation of the Effects of MMR Immunization and Mercury Doses from Thimerosal-Containing Childhood Vaccines on the Population Prevalence of Autism” and “Pediatric MMR Vaccination Safety”
Premise
These studies were among the few publications cited by petitioners as suggesting a positive association between vaccines and autism.
Results
They purported to identify relationships between vaccine exposure and autism prevalence.
Conclusions of the Authors
The authors advanced conclusions supportive of vaccine-autism causation.
Court’s Evaluation
The OAP decisions gave these studies essentially no evidentiary weight. The special masters described them as methodologically deficient and noted that they had been heavily criticized by reviewers, by petitioners’ own epidemiology expert, and by other courts. In the thimerosal decisions especially, the Geier articles were treated as too unreliable to assist petitioners.
Hansen et al.
“Regression in Autism: Prevalence and Associated Factors in the CHARGE Study” (Ambulatory Pediatrics, 2008)
Premise
This study examined the prevalence of regression in children with autism and how rates varied depending on the definition of regression used.
Results
When regression was defined as loss of both social skills and language, 15% of children were classified as regressed. When regression was defined more broadly as loss of either language or social skills, an additional 26% were captured, for a total of 41%.
Conclusions of the Authors
The study showed that regression is a significant and variably defined phenomenon within autism, depending on the criteria used.
Court’s Evaluation
The thimerosal and MMR opinions used Hansen not to support petitioners’ theory, but to show that regression is not rare, novel, or necessarily a distinct vaccine-linked phenotype. It helped the courts explain why regression, by itself, did not prove a different cause.
Final Analysis
Once the additional studies are included, the pattern becomes even clearer. The OAP courts were not choosing between one positive study and one negative study. They were faced with a broad scientific record in which numerous epidemiologic studies from multiple countries, using cohort, case-control, ecologic, and subgroup analyses, repeatedly failed to show that MMR or thimerosal-containing vaccines caused autism, regressive autism, bowel-associated autism, or any new vaccine-linked autism phenotype. The special masters acknowledged that epidemiology cannot mathematically eliminate every theoretical possibility, especially a tiny hypothetical subgroup. But they held that the literature actually before them did not support such a subgroup and, taken as a whole, weighed strongly against the petitioners’ theories.
Case Law Analysis: How the Vaccine Court Addressed Autism Claims
While the medical literature formed the scientific foundation of the Omnibus Autism Proceeding, the Vaccine Injury Compensation Program ultimately had to answer a legal question: whether the available scientific evidence demonstrated, by a preponderance of the evidence, that vaccines can cause autism. To address that question, the Court selected a series of **test cases—Cedillo, Hazlehurst, Snyder, King, Dwyer, and Mead—**to examine the competing medical theories and the extensive scientific record developed by both parties. These cases allowed the Court to evaluate expert testimony, analyze hundreds of peer-reviewed studies, and determine whether petitioners had presented a reliable medical theory causally linking vaccination to autism. The decisions that followed did not simply reject individual claims; they created a detailed legal framework explaining how courts evaluate complex medical evidence, how scientific literature is weighed under the Vaccine Act, and why the evidence presented in the autism test cases ultimately failed to establish vaccine causation under the governing legal standard.
Cedillo v. Secretary of Health and Human Services
(Special Master Decision 2009; aff’d, 89 Fed. Cl. 158 (2009); aff’d, 617 F.3d 1328 (Fed. Cir. 2010))
Cedillo was one of the lead test cases in the Omnibus Autism Proceeding, a coordinated set of Vaccine Program cases designed to evaluate whether childhood vaccines can cause autism. Petitioners alleged that Michelle Cedillo developed autism after receiving the MMR vaccine along with thimerosal-containing vaccines. Petitioners advanced a multi-step medical theory: thimerosal exposure allegedly impaired Michelle’s immune system; the MMR vaccine then introduced measles virus that persisted in her body; that persistent infection caused gastrointestinal disease; and the virus ultimately affected the brain and caused autism.
The Special Master evaluated extensive expert testimony and a large body of scientific literature addressing mercury toxicity, immune dysfunction, measles virus persistence, and epidemiology of autism and vaccination. Petitioners relied heavily on studies suggesting persistent measles infection, particularly the Uhlmann PCR study, as well as toxicology literature concerning thimerosal. Respondent countered with numerous epidemiological studies finding no association between MMR vaccination and autism and with molecular studies—such as research by D’Souza and Afzal—that failed to replicate claims of measles virus persistence.
The Special Master concluded that petitioners failed to demonstrate that vaccines can cause autism or that vaccines caused Michelle Cedillo’s condition. He found the measles persistence evidence unreliable due to methodological problems and lack of replication and concluded that the epidemiological literature consistently showed no causal association between MMR vaccination and autism.
Petitioners sought review in the Court of Federal Claims, arguing that the Special Master misinterpreted the scientific literature and improperly discounted their experts. The court affirmed, holding that the Special Master carefully evaluated the evidence and reasonably rejected petitioners’ causation theory.
Petitioners then appealed to the Federal Circuit, which again affirmed. The appellate court held that the Special Master’s evaluation of the scientific evidence and expert testimony was entitled to substantial deference and was well supported by the record. The Federal Circuit concluded that the evidence did not establish that vaccines caused Michelle Cedillo’s autism, leaving the denial of compensation intact.
Dwyer v. Secretary of Health and Human Services
(Special Master Decision, 2010 – Omnibus Autism Proceeding Theory 2 Test Case)
Dwyer was one of the three “Theory 2” test cases in the Omnibus Autism Proceeding (OAP), addressing the claim that thimerosal-containing vaccines (“TCVs”)—specifically the ethylmercury preservative used in certain childhood vaccines—can cause autism spectrum disorders (“ASDs”). Petitioners Timothy and Maria Dwyer alleged that their son, Colin Dwyer, developed autism due to exposure to mercury contained in thimerosal-containing vaccines administered during infancy.
Petitioners advanced a multi-part medical theory built largely on expert testimony from Drs. Aposhian, Deth, and Kinsbourne. They argued that ethylmercury exposure from vaccines produced metabolic disruption, oxidative stress, and neuroinflammation in susceptible children. According to petitioners, these biochemical effects interfered with neuronal signaling and ultimately produced the behavioral and developmental symptoms of autism. Petitioners further asserted that a subgroup of children—described as having “clearly regressive autism”—might possess a genetic hypersensitivity to mercury, rendering them uniquely vulnerable to vaccine-related neurotoxicity.
The government presented extensive expert testimony from epidemiologists, neurologists, toxicologists, and autism researchers who argued that petitioners’ hypotheses were biologically implausible and inconsistent with the known effects of mercury on the brain. Respondent emphasized that epidemiological studies examining populations exposed to thimerosal-containing vaccines had consistently failed to show any association with autism. Respondent’s experts also explained that the biochemical mechanisms proposed by petitioners did not resemble known manifestations of mercury toxicity and were unsupported by reliable experimental evidence.
After reviewing a voluminous record that included expert testimony, scientific literature, and extensive medical research, Special Master Denise Vowell concluded that petitioners failed to establish by a preponderance of the evidence that thimerosal-containing vaccines can cause autism or that they caused Colin Dwyer’s condition. The decision found petitioners’ causation theories scientifically unreliable and unsupported by the broader body of medical literature. Accordingly, the Special Master denied compensation under the Vaccine Act.
Hazlehurst v. Secretary of Health and Human Services
(Special Master Decision, 2009; aff’d, 88 Fed. Cl. 473 (2009); aff’d, 604 F.3d 1343 (Fed. Cir. 2010))
Hazlehurst was one of the three Theory 1 test cases in the Omnibus Autism Proceeding (OAP), addressing the claim that autism can result from a combination of the MMR vaccine and thimerosal-containing vaccines. Petitioners Rolf and Angela Hazlehurst alleged that their son, Yates Hazlehurst, developed regressive autism following his receipt of routine childhood vaccines, including the MMR vaccine administered shortly before his first birthday. Prior to vaccination, Yates reportedly developed normally; however, within months of receiving the MMR vaccine he exhibited behavioral regression, loss of speech, hyperactivity, and gastrointestinal symptoms.
Petitioners advanced a theory that the measles component of the MMR vaccine caused immune dysfunction that prevented clearance of the measles virus. According to this hypothesis, persistent measles infection in the gastrointestinal tract led to chronic inflammation that spread to the brain and ultimately produced neurological injury manifesting as autism. Petitioners’ experts relied heavily on studies reporting the detection of measles virus in intestinal tissue of autistic children, including research associated with Andrew Wakefield and testing performed by the Unigenetics laboratory. Respondent challenged these studies and presented expert testimony explaining that the measles persistence hypothesis lacked biological plausibility and that the laboratory testing methods underlying the purported findings were unreliable.
The Special Master concluded that petitioners failed to establish a reliable medical theory linking the MMR vaccine to autism. Central to the ruling was the determination that the measles persistence evidence—described as the “linchpin” of petitioners’ theory—was scientifically unreliable because the underlying studies were methodologically flawed and had not been replicated by independent laboratories. The Special Master further found that epidemiological studies consistently showed no association between MMR vaccination and autism. Accordingly, the Special Master held that petitioners failed to satisfy the first two prongs of the Althen causation test and denied compensation.
Petitioners sought review in the Court of Federal Claims, arguing that the Special Master improperly relied on evidence discrediting the Unigenetics laboratory and failed to consider evidence supporting measles persistence. The court rejected these arguments and affirmed the Special Master’s decision, holding that the evaluation of scientific evidence and expert testimony was reasonable and supported by the record. The court also agreed that petitioners had not established a reliable medical theory linking vaccination to autism and therefore failed to meet their burden under the Vaccine Act.
Snyder v. Secretary of Health and Human Services
(Special Master Decision, 2009; aff’d, 88 Fed. Cl. 706 (2009))
Snyder was the third “Theory 1” test case in the Omnibus Autism Proceeding (“OAP”), which examined the claim that autism can result from the combined effects of thimerosal-containing vaccines (“TCVs”) and the measles component of the MMR vaccine. Petitioners Kathryn and Joseph Snyder alleged that their son, Colten Snyder, developed a pervasive developmental disorder (“PDD”), a condition within the autism spectrum, after receiving routine childhood vaccinations including MMR at fifteen months of age. Petitioners advanced a multi-step biological theory: that ethylmercury contained in TCVs suppresses immune function; that the measles component of the MMR vaccine further impairs immune response; that the combined immune suppression allows the attenuated measles virus to persist in the body; and that persistent measles infection ultimately reaches the brain and causes neurological injury manifesting as autism.
The Special Master reviewed an extensive evidentiary record consisting of expert testimony across multiple scientific disciplines, including virology, immunology, neurology, toxicology, epidemiology, and gastroenterology, along with hundreds of medical journal articles and laboratory studies. Petitioners relied heavily on expert opinions proposing immune dysregulation and measles virus persistence, while respondent presented epidemiological research showing no association between vaccines and autism and expert testimony explaining that autism is strongly genetic and typically arises from prenatal neurodevelopmental abnormalities. The court also evaluated laboratory testing allegedly detecting measles virus in biological samples, ultimately finding significant methodological problems and reliability concerns with those results.
After weighing the scientific evidence and expert testimony, the Special Master concluded that petitioners failed to establish by a preponderance of the evidence that vaccines can cause autism or that they caused Colten Snyder’s condition. The decision found petitioners’ theories speculative, unsupported by reliable medical research, and inconsistent with the broader body of scientific literature. The Court of Federal Claims later affirmed the decision, holding that the Special Master’s evaluation of the scientific evidence and credibility determinations were well supported by the record and entitled to deference.
King v. Secretary of Health and Human Services
(Special Master Decision, 2010)
King was one of the three “Theory 2” test cases in the Omnibus Autism Proceeding addressing the claim that thimerosal-containing vaccines alone can cause autism. Petitioners alleged that Jordan King developed autism spectrum disorder following exposure to pediatric vaccines that contained thimerosal, a mercury-based preservative. Petitioners advanced a biological theory that ethylmercury from vaccines accumulates in the brain as inorganic mercury, triggering oxidative stress, neuroinflammation, and disruptions in neuronal signaling that ultimately lead to autistic regression. Petitioners relied on toxicology literature concerning mercury metabolism and cellular studies suggesting that thimerosal can affect immune or neurological function.
Respondent challenged the biological plausibility of this theory and presented extensive expert testimony from toxicologists, neurologists, epidemiologists, and autism researchers. Respondent’s experts emphasized that mercury poisoning produces clinical symptoms different from autism and that epidemiological studies examining large populations had consistently failed to show any association between thimerosal exposure and autism. Respondent also argued that the petitioners’ reliance on biochemical hypotheses lacked reliable experimental support.
After evaluating the expert testimony and the scientific literature, the Special Master concluded that petitioners failed to demonstrate a reliable medical theory connecting thimerosal exposure to autism. The decision held that the proposed biological mechanisms were speculative and unsupported by the broader scientific evidence. Because petitioners failed to establish general causation under the Vaccine Act, the claim for compensation was denied.
Mead v. Secretary of Health and Human Services
(Special Master Decision, 2010)
Mead was another test case in the Omnibus Autism Proceeding addressing the theory that thimerosal-containing vaccines can cause regressive autism. Petitioners George and Victoria Mead alleged that their son William developed regressive autism after receiving routine childhood vaccinations containing thimerosal. Petitioners’ theory proposed that ethylmercury from vaccines accumulated in the brain as inorganic mercury, creating oxidative stress and neuroinflammation that disrupted neuronal signaling. Petitioners further argued that this neuroinflammatory process caused the developmental regression characteristic of certain autism cases.
Petitioners relied on expert testimony and various biochemical and toxicological studies addressing mercury metabolism, oxidative stress, and glutathione depletion. They also argued that epidemiological studies examining autism generally failed to detect an association because they did not isolate a specific subgroup of “clearly regressive” autism cases. Respondent countered with expert testimony from neurologists, epidemiologists, toxicologists, and autism researchers who argued that autism arises primarily from prenatal neurodevelopmental abnormalities and genetic influences. Respondent also relied on numerous epidemiological studies demonstrating no association between thimerosal-containing vaccines and autism.
After reviewing extensive scientific literature and expert testimony, the Special Master concluded that petitioners failed to establish a scientifically reliable medical theory linking thimerosal exposure to autism. The court found petitioners’ hypotheses biologically implausible and inconsistent with the weight of the epidemiological evidence. Because petitioners failed to establish both general and specific causation, the claim for compensation was dismissed.
Encephalitis Induced Autism
Autoimmune Encephalitis, Developmental Regression, and Autism-Like Outcomes
One important neurological condition—autoimmune encephalitis (AE)—demonstrates why some children who appear to develop autism after a period of normal development may actually be experiencing a distinct brain injury rather than idiopathic autism. Autoimmune encephalitis is a group of disorders in which the immune system mistakenly attacks brain tissue, producing inflammation of the central nervous system and a wide range of neurological and psychiatric symptoms. These symptoms frequently include seizures, behavioral changes, cognitive impairment, language loss, and developmental regression. (PubMed)
A growing body of medical literature has documented that AE can produce autism spectrum disorder (ASD) or autism-like features, particularly when the condition occurs in early childhood. A 2021 review examining the relationship between autoimmune encephalitis and autism concluded that AE may either act as a causative neurological event leading to ASD-type symptoms or produce clinical features that closely mimic autism, resulting in misdiagnosis. (PMC)
This relationship is especially relevant in cases of autistic regression, where a previously healthy toddler loses language, social engagement, and developmental milestones. Research has documented that inflammatory brain diseases—including autoimmune encephalitis and viral encephalitis—can precipitate such regression, producing symptoms identical to those seen in autism spectrum disorders. (Thinking Autism Taking Action)
Clinically, AE often presents with sudden developmental regression, behavioral abnormalities, language loss, and neurological symptoms that overlap with core autism features. Because the immune-mediated inflammation directly affects brain function, the resulting developmental delays may persist even after the acute illness resolves. (Psych Central)
This distinction has important implications for vaccine injury law. Encephalitis and encephalopathy are compensable neurological injuries under the Vaccine Injury Compensation Program (VICP) when they occur following vaccination within the appropriate medical timeframe. If a toddler develops autoimmune encephalitis and subsequently demonstrates developmental regression or autism-like symptoms, the compensable injury is the brain inflammation itself, not autism as an independent diagnosis.
Understanding this medical pathway is critical because it illustrates how a neurological injury recognized by the Vaccine Program—autoimmune encephalitis—can lead to long-term developmental outcomes that resemble autism. The literature therefore highlights an important clinical reality: some cases labeled as autism may actually represent the neurological consequences of immune-mediated brain injury.
Legal Analysis on Autism Claims
Legal Analysis: What the Vaccine Court Actually Decided About Vaccines and Autism
For more than two decades, courts and scientists have examined whether childhood vaccines—particularly the measles-mumps-rubella (MMR) vaccine and vaccines that once contained thimerosal—can cause autism. Thousands of petitions raising that claim were filed in the National Vaccine Injury Compensation Program (VICP). Because of the volume and the complexity of the scientific issues, the Court consolidated many of those cases into the Omnibus Autism Proceeding (OAP) and selected several test cases—Cedillo, Hazlehurst, Snyder, King, Dwyer, and Mead—to evaluate the competing medical theories and scientific evidence.
From a legal standpoint, the question before the Court was not whether science had reached absolute certainty. The Vaccine Program does not require scientific certainty. Instead, the legal standard is preponderance of the evidence—whether a causal connection is more likely than not (greater than 50%). The special masters reviewed an enormous scientific record, including hundreds of peer-reviewed articles, epidemiological studies, toxicology research, molecular biology studies, and expert testimony from leading physicians and scientists across multiple disciplines. After evaluating that evidence, the Court concluded that the available medical literature did not establish that vaccines cause autism by a preponderance of the evidence.
That conclusion is frequently misunderstood. The Court did not hold that autism can never follow vaccination, nor did it say that science has answered every question about autism. Rather, the Court determined that the scientific record—particularly the large epidemiological studies examining hundreds of thousands of children—does not demonstrate that vaccines themselves are a direct cause of autism.
Modern medical research consistently describes autism as a multifactorial neurodevelopmental condition. Studies cited in the OAP and subsequent research identify several contributing influences, including:
Genetic factors and inherited susceptibility
Prenatal neurological development abnormalities
Environmental influences during pregnancy or early development
Immune dysregulation and neuroinflammation in some cases
Perinatal or early childhood neurological injury
Because vaccines are administered during infancy and early childhood—precisely when developmental milestones are rapidly emerging—it is understandable that parents may associate the timing of vaccination with the onset of behavioral or developmental changes. But temporal association alone does not establish causation. When millions of children receive vaccines during the same developmental window in which autism symptoms typically emerge, coincidental timing is inevitable. The Vaccine Court concluded that this coincidence does not constitute proof that vaccines are the cause of autism.
At the same time, the medical literature recognizes that neurological injuries following vaccination can occur, and those injuries are compensable under the Vaccine Injury Compensation Program. One such condition is autoimmune encephalitis (AE)—an immune-mediated inflammation of the brain that can produce seizures, behavioral disturbances, language loss, cognitive impairment, and developmental regression. In young children, the long-term neurological consequences of encephalitis can include persistent developmental delay and autism-like symptoms.
This distinction is critically important. In cases where a child develops autoimmune encephalitis following vaccination and later manifests autism-spectrum symptoms, the causal pathway is not “vaccine causes autism.” Instead, the medically recognized pathway is:
Vaccine → Autoimmune Encephalitis → Neurological Injury → Autism-like Developmental Sequelae
The compensable injury in that scenario is the brain inflammation itself, which is a recognized neurological injury under the Vaccine Program. The later developmental condition—whether diagnosed as autism spectrum disorder, developmental delay, or cognitive impairment—is part of the sequelae of the encephalitic injury.
In other words:
Vaccine → Autism was the theory tested in the Omnibus Autism Proceeding and was not proven by a preponderance of the evidence.
Vaccine → Autoimmune Encephalitis → Autism-like outcomes is a medically plausible pathway recognized in neurological literature and consistent with injuries compensable under the Vaccine Program.
For families navigating the Vaccine Program, that distinction matters. The presence of an autism diagnosis should not be treated as an automatic exclusion from compensation when the evidence shows that a vaccine caused a neurological injury—such as encephalitis—that later resulted in developmental regression or autism-spectrum symptoms.
Finally, an important lesson from the Omnibus Autism Proceeding is that science is not static. Medical understanding evolves, and legal analysis must evolve with it. The OAP decisions reflect the best available evidence at the time those cases were litigated. As research advances, our understanding of neurological injury, immune-mediated brain disorders, and developmental outcomes will continue to develop. Rather than prematurely assigning blame without reliable scientific proof, the better path forward is continued rigorous research. Rare conditions such as autoimmune encephalitis and other immune-mediated neurological injuries deserve further study so that the scientific community can better understand their causes, mechanisms, and long-term outcomes. Encouraging that research—while fairly compensating those who suffer genuine vaccine-related neurological injuries—is the responsible and scientifically grounded approach.